JCNRJournal of Clinical and Nursing Research2208-36852208-3693Bio-Byword Scientific Publishing Pty. Ltd.10.26689/jcnr.v9i7.11489ArticleResearch Advances in the CX3CL1/CX3CR1 Signaling Pathway: Implications for Atherosclerosishttps://artdesignp.com/journal/JCNR/9/7/10.26689/jcnr.v9i7.11489ChengSha,HeZhiling,QianGuiying,HuangGuilan,ChenQuanfu2025972025-08-04The CX3CL1/CX3CR1 signaling axis is established as a pivotal regulator in the pathogenesis of atherosclerosis, with well-documented roles in orchestrating inflammatory responses, mediating immune cell recruitment, and influencing vascular remodeling. This review provides a comprehensive synthesis of current knowledge regarding the structural characteristics and functional properties of the CX3CL1/CX3CR1 pathway. This study delves into its specific mechanistic contributions to atherosclerosis, placing particular emphasis on its regulatory influence across diverse cell types, including arterial endothelial cells, smooth muscle cells, and macrophages. Furthermore, the pathway’s integral involvement in both the initiation and progression of atherosclerotic plaques is dissected, highlighting its critical impact on plaque stability and susceptibility to rupture. The review also extends to the pathogenic significance of CX3CL1/CX3CR1 signaling in atherosclerosis-related comorbidities, incorporating the latest advancements in understanding its roles in coronary heart disease, stroke, and other cardiovascular disorders. By critically integrating findings from the extant literature, this review constructs a foundational framework to guide future investigations and underscores the substantial translational potential of targeting this pathway for therapeutic intervention in clinical settings.

Libby P, Ridker PM, Maseri A, 2002, Inflammation and Atherosclerosis. Circulation, 105(9): 1135–1143.

Björkegren JL, Lusis AJ, 2022, Atherosclerosis: Recent Developments. Cell, 185(10): 1630–1645

Hansson GK, Hermansson A, 2011, The Immune System in Atherosclerosis. Nature Immunology, 12(3): 204–212.

Weber C, Schober A, Zernecke A, 2004, Chemokines: Key Regulators of Mononuclear Cell Recruitment in Atherosclerotic Vascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 24(11): 1997–2008.

Zernecke A, Shagdarsuren E, Weber C, 2008, Chemokines in Atherosclerosis: An Update. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(11): 1897–1908.

Imaizumi T, Yoshida H, Satoh K, 2004, Regulation of CX3CL1/Fractalkine Expression in Endothelial Cells. Journal of Atherosclerosis and Thrombosis, 11(1): 15–21.

Lee M, Lee Y, Song J, et al., 2018, Tissue-Specific Role of CX3CR1 Expressing Immune Cells and Their Relationships with Human Disease. Immune Network, 18(1).

Combadière C, Potteaux S, Rodero M, et al., 2008, Combined Inhibition of CCL2, CX3CR1, and CCR5 Abrogates Ly6Chi and Ly6Clo Monocytosis and Almost Abolishes Atherosclerosis in Hypercholesterolemic Mice. Circulation, 117(13): 1649–1657.

Landsman L, Bar-On L, Zernecke A, et al., 2009, CX3CR1 Is Required for Monocyte Homeostasis and Atherogenesis by Promoting Cell Survival. Blood, 113(4): 963–972.

Imai T, Hieshima K, Haskell C, et al., 1997, Identification and Molecular Characterization of Fractalkine Receptor CX3CR1, Which Mediates Both Leukocyte Migration and Adhesion. Cell, 91(4): 521–530.

Bazan JF, Bacon KB, Hardiman G, et al., 1997, A New Class of Membrane-Bound Chemokine with a CX3C Motif. Nature, 385(6617): 640–644.

Hundhausen C, Misztela D, Berkhout TA, et al., 2003, The Disintegrin-Like Metalloproteinase ADAM10 Is Involved in Constitutive Cleavage of CX3CL1 (Fractalkine) and Regulates CX3CL1-Mediated Cell-Cell Adhesion. Blood, 102(4): 1186–1195.

Geissmann F, Jung S, Littman DR, 2003, Blood Monocytes Consist of Two Principal Subsets with Distinct Migratory Properties. Immunity, 19(1): 71–82.

Zhang X, Feng X, Cai W, et al., 2015, Chemokine CX3CL1 and Its Receptor CX3CR1 Are Associated with Human Atherosclerotic Lesion Vulnerability. Thrombosis Research, 135(6): 1147–1153.

Tacke F, Alvarez D, Kaplan TJ, et al., 2007, Monocyte Subsets Differentially Employ CCR2, CCR5, and CX3CR1 to Accumulate Within Atherosclerotic Plaques. The Journal of Clinical Investigation, 117(1): 185–194.

Lesnik P, Haskell CA, Charo IF, 2003, Decreased Atherosclerosis in CX3CR1–/– Mice Reveals a Role for Fractalkine in Atherogenesis. The Journal of Clinical Investigation, 111(3): 333–340.

Wang K, Jiang L, Hu A, et al., 2021, Vertebral-Specific Activation of the CX3CL1/ICAM-1 Signaling Network Mediates Non-Small-Cell Lung Cancer Spinal Metastasis by Engaging Tumor Cell–Vertebral Bone Marrow Endothelial Cell Interactions. Theranostics, 11(10): 4770.

Korbecki J, Simińska D, Kojder K, et al., 2020, Fractalkine/CX3CL1 in Neoplastic Processes. International Journal of Molecular Sciences, 21(10): 3723.

Popiolek-Barczyk K, Mika J, 2016, Targeting the Microglial Signaling Pathways: New Insights in the Modulation of Neuropathic Pain. Current Medicinal Chemistry, 23(26): 2908–2928.

Lee SG, Oh J, Bong SK, et al., 2018, Macrophage Polarization and Acceleration of Atherosclerotic Plaques in a Swine Model. PloS One, 13(3): e0193005.

Poupel L, Boissonnas A, Hermand P, et al., 2013, Pharmacological Inhibition of the Chemokine Receptor, CX3CR1, Reduces Atherosclerosis in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 33(10): 2297–2305.

Apostolakis S, Spandidos D, 2013, Chemokines and Atherosclerosis: Focus on the CX3CL1/CX3CR1 Pathway. Acta Pharmacologica Sinica, 34(10): 1251–1256.

Liu H, Jiang D, 2011, Fractalkine/CX3CR1 and Atherosclerosis. Clinica Chimica Acta, 412(13–14): 1180–1186.

Imaizumi T, Yoshida H, Satoh K, 2004, Regulation of CX3CL1/Fractalkine Expression in Endothelial Cells. Journal of Atherosclerosis and Thrombosis, 11(1): 15–21.

Gomez D, Owens GK, 2012, Smooth Muscle Cell Phenotypic Switching in Atherosclerosis. Cardiovascular Research, 95(2): 156–164.

Liu ZJ, Tan Y, Beecham GW, et al., 2012, Notch Activation Induces Endothelial Cell Senescence and Pro-Inflammatory Response: Implication of Notch Signaling in Atherosclerosis. Atherosclerosis, 225(2): 296–303.

Woollard KJ, Geissmann F, 2010, Monocytes in Atherosclerosis: Subsets and Functions. Nature Reviews Cardiology, 7(2): 77–86.

Zernecke A, Weber C, 2010, Chemokines in the Vascular Inflammatory Response of Atherosclerosis. Cardiovascular Research, 86(2): 192–201.

Zhang H, Guo C, Wu D, et al., 2012, Hydrogen Sulfide Inhibits the Development of Atherosclerosis with Suppressing CX3CR1 and CX3CL1 Expression. PloS One, 7(7): e41147.

Altara R, Manca M, Brandão RD, et al., 2016, Emerging Importance of Chemokine Receptor CXCR3 and Its Ligands in Cardiovascular Diseases. Clinical Science, 130(7): 463–478.

Combadière C, Potteaux S, Rodero M, et al., 2008, Combined Inhibition of CCL2, CX3CR1, and CCR5 Abrogates Ly6Chi and Ly6Clo Monocytosis and Almost Abolishes Atherosclerosis in Hypercholesterolemic Mice. Circulation, 117(13): 1649–1657.

Tsou CL, Peters W, Si Y, Slaymaker S, et al., 2007, Critical Roles for CCR2 and MCP-3 in Monocyte Mobilization from Bone Marrow and Recruitment to Inflammatory Sites. The Journal of Clinical Investigation, 117(4): 902–909.

Damås JK, Boullier A, Wæhre T, et al., 2005, Expression of Fractalkine (CX3CL1) and Its Receptor, CX3CR1, Is Elevated in Coronary Artery Disease and Is Reduced During Statin Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology, 25(12): 2567–2572.

Clark AK, Staniland AA, Malcangio M, 2011, Fractalkine/CX3CR1 Signalling in Chronic Pain and Inflammation. Current Pharmaceutical Biotechnology, 12(10): 1707–1714.

Lucas AD, Bursill C, Guzik TJ, et al., 2003, Smooth Muscle Cells in Human Atherosclerotic Plaques Express the Fractalkine Receptor CX3CR1 and Undergo Chemotaxis to the CX3C Chemokine Fractalkine (CX3CL1). Circulation, 108(20): 2498–2504.

Li C, He J, Zhong X, et al., 2018, CX3CL1/CX3CR1 Axis Contributes to Angiotensin II-Induced Vascular Smooth Muscle Cell Proliferation and Inflammatory Cytokine Production. Inflammation, 41: 824–834.

Li G, Xu Y, Sheng X, et al., 2017, Naringin Protects Against High Glucose-Induced Human Endothelial Cell Injury via Antioxidation and CX3CL1 Downregulation. Cellular Physiology and Biochemistry, 42(6): 2540–2551.

Ma J, Luo J, Sun Y, et al., 2022, Cytokines Associated with Immune Response in Atherosclerosis. American Journal of Translational Research, 14(9): 6424.

Rowinska Z, Koeppel TA, Sanati M, et al., 2017, Role of the CX3C Chemokine Receptor CX3CR1 in the Pathogenesis of Atherosclerosis After Aortic Transplantation. PloS One, 12(2): e0170644.

Tiwari RL, Singh V, Barthwal MK, 2008, Macrophages: An Elusive Yet Emerging Therapeutic Target of Atherosclerosis. Medicinal Research Reviews, 28(4): 483–544.

Gimbrone MA Jr, García-Cardeña G, 2016, Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circulation Research, 118(4): 620–636.

Roy-Chowdhury E, Brauns N, Helmke A, Nordlohne J, Bräsen JH, Schmitz J, von Vietinghoff S, 2021, Human CD16+ Monocytes Promote a Pro-Atherosclerotic Endothelial Cell Phenotype via CX3CR1–CX3CL1 Interaction. Cardiovascular Research, 117(6): 1510–1522.

Kasama T, Wakabayashi K, Sato M, et al., 2010, Relevance of the CX3CL1/Fractalkine–CX3CR1 Pathway in Vasculitis and Vasculopathy. Translational Research, 155(1): 20–26.

Combadière C, Potteaux S, Rodero M, et al., 2008, Combined Inhibition of CCL2, CX3CR1, and CCR5 Abrogates Ly6Chi and Ly6Clo Monocytosis and Almost Abolishes Atherosclerosis in Hypercholesterolemic Mice. Circulation, 117(13): 1649–1657.

Moatti D, Faure S, Fumeron F, et al., 2001, Polymorphism in the Fractalkine Receptor CX3CR1 as a Genetic Risk Factor for Coronary Artery Disease. Blood, 97(7): 1925–1928.

Kim KW, Ivanov S, Williams JW, 2020, Monocyte Recruitment, Specification, and Function in Atherosclerosis. Cells, 10(1): 15.

Li R, Frangogiannis NG, 2021, Chemokines in Cardiac Fibrosis. Current Opinion in Physiology, 19: 80–91.

Dénes Á, Humphreys N, Lane TE, et al., 2010, Chronic Systemic Infection Exacerbates Ischemic Brain Damage via a CCL5 (Regulated on Activation, Normal T-Cell Expressed and Secreted)-Mediated Proinflammatory Response in Mice. Journal of Neuroscience, 30(30): 10086–10095.

Tomaszewski M, Bębnowska D, Hrynkiewicz R, et al., 2021, Role of the Immune System Elements in Pulmonary Arterial Hypertension. Journal of Clinical Medicine, 10(16): 3757.

Wong BW, Wong D, McManus BM, 2002, Characterization of Fractalkine (CX3CL1) and CX3CR1 in Human Coronary Arteries with Native Atherosclerosis, Diabetes Mellitus, and Transplant Vascular Disease. Cardiovascular Pathology, 11(6): 332–338.